A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
We compared the effects of ibandronate and pamindronate in patients with bone metastases from breast or lung cancer and we found that ibandronate is superior to pamindronate in alleviating pain, improving mobility and quality of life, and reducing bone resorption indices in patients with bone metastases from breast or lung cancer.
Heras
Panagiotis
P
General Hospital of Nafplio, Department of Internal Medicine, Nafplio, Greece. panheras@yahoo.com
Hatzopoulos
Antonios
A
Heras
Vasilios
V
Kritikos
Nikolaos
N
Karagiannis
Stefanos
S
Kritikos
Konstantinos
K
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001862:Bone Resorption / Q000188:drug therapy / Q000209:etiology; D001943:Breast Neoplasms / Q000150:complications; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008175:Lung Neoplasms; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D000077268:Pamidronate; D011788:Quality of Life
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate; D000077557:Ibandronic Acid